Hologic, Inc. (NASDAQ:HOLX) Short Interest Down 25.0% in February

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) was the target of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 4,440,000 shares, a drop of 25.0% from the February 13th total of 5,920,000 shares. Based on an average daily trading volume, of 2,420,000 shares, the short-interest ratio is presently 1.8 days. Currently, 2.0% of the company's shares are sold short.

Analysts Set New Price Targets

HOLX has been the subject of several recent research reports. Stephens restated an "overweight" rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Jefferies Financial Group initiated coverage on Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price objective for the company. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Wolfe Research initiated coverage on shares of Hologic in a report on Friday, December 13th. They set a "peer perform" rating for the company. Finally, Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $84.62.

Remove Ads

Hedge Funds Weigh In On Hologic

Large investors have recently added to or reduced their stakes in the business. General Partner Inc. purchased a new stake in shares of Hologic in the fourth quarter worth approximately $26,000. Groupama Asset Managment boosted its holdings in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC grew its stake in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Stock Down 0.7 %

Hologic stock traded down $0.46 during mid-day trading on Thursday, reaching $61.01. The stock had a trading volume of 3,109,732 shares, compared to its average volume of 2,431,954. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic has a fifty-two week low of $60.33 and a fifty-two week high of $84.67. The stock's 50-day simple moving average is $66.50 and its 200-day simple moving average is $74.28. The firm has a market capitalization of $13.69 billion, a PE ratio of 19.25, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts forecast that Hologic will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.